 |
|
 |
| |
One of IZB |
|
| |
|
|
| |
press releases |
|
| |
|
|
| |
4SC to host conference call on 14 May 2013 to present first quarter results of 2013
10.05.2013
| |
| |
|
|
| |
Evotec extends drug discovery alliance with Genentech
22.04.2013
| |
| |
|
|
| |
ChromoTek wins INDUSTRY PRIZE 2013 for its pioneering Chromobody® technology for the real time analysis of cellular molecules in live cells
18.04.2013
| |
| |
|
|
| |
4SC to present at two upcoming investor conferences
12.04.2013
| |
| |
|
|
| |
Analysis of complex protein-protein-interactions made easy: ChromoTek’s fluorescent two hybrid (F2H®) technology enables screening and validation of compounds in living cells
04.04.2013
| |
| |
|
|
| |
Forward step by step with Action Plan 2016 - Continued revenue growth - Significant pipeline progress
26.03.2013
| |
| |
|
|
| |
4SC AG announces financial results for a successful year 2012
25.03.2013
| |
| |
|
|
| |
4SC to host conference cann and webcast on 25 March 2013 to present full year financial results for 2012
18.03.2013
| |
| |
|
|
| |
ibidi is a Top Winner in the 2012/13 German Economy Innovation Award Competition
11.03.2013
| |
| |
|
|
| |
Biomolecular movies: Chromotek introduces Chromobody® plasmids for real time monitoring of key intracellular target molecules in vivo
11.03.2013
| |
| |
|
|
| |
4SC AG: Dr. Ulrich Dauer to step down as CEO and member of the Management Board on 31 March 2013; his successor will be CFO Enno Spillner
06.03.2013
| |
| |
|
|
| |
4SC Discovery and LEO Pharma announce exclusive research and license agreement for inflammatory skin diseases
26.02.2013
| |
| |
|
|
| |
4SC Discovery and BioNTech launch strategic cancer therapy research partnership
20.02.2013
| |
| |
|
|
| |
LGC Standards announces distribution partnership with Biontex
15.01.2013
| |
| |
|
|
| |
Evotec achieves milestone in drug discovery collaboration with Ono Pharmaceutical Co., Ltd.
11.01.2013
| |
| |
|
|
| |
Evotec and Yale University form Open Innovation Alliance
09.01.2013
| |
| |
|
|
| |
4SC obtains key patent for anti-cancer compound resminostat in Europe
08.01.2013
| |
| |
|
|
| |
Evotec expands collaboration with MedImmune, receives milestone payment
07.01.2013
| |
| |
|
|
| |
Evotec acquires Cell Culture Service GmbH
03.01.2013
| |
| |
|
|
| |
Evotec and Apeiron Biologics announce collaboration on cancer immunotherapy
02.01.2013
| |
| |
|
|
| |
ibidi is a Finalist in the 2012/13 German Economy Innovation Award Competition
19.12.2012
| |
| |
|
|
| |
Evotec announces NMDA antagonist license agreement
17.12.2012
| |
| |
|
|
| |
SuppreMol’s SM101 shows a sustained clinical activity and a favorable safety profile in Primary Immune Thrombocytopenia (ITP) patients
10.12.2012
| |
| |
|
|
| |
4SC reports positive data from clinical Phase I trial with 4SC-205 in cancer patients and initiates study amendment to further investigate the compound based on new preclinical and clinical findings
05.12.2012
| |
| |
|
|
| |
Evotec enters biology collaboration with Probiodrug
Hamburg, Germany – 28 November 2012: Evotec AG (Frankfurt
Stock Exchange: EVT, TecDAX) announced today that it has entered
into a collaboration with Probiodrug AG, a privately owned
biopharmaceutical company focused on the development of innova...
28.11.2012
| |
| |
|
|
| |
Evotec Receives CIR (French Research Tax Credit) Accreditation
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) today announced that it has received CIR accreditation for a three-year period from the French Ministry of Higher Education and Research.
23.11.2012
| |
| |
|
|
| |
archive >>> |
|